Articoli anno 1999


Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil
Ishikawa T, Ichida T, Ishimoto Y, Yokoyama J, Nomoto M, Ebe Y, Usuda H, Naito M, Asakura H Third Department of Internal Medicine, Niigata University School of Medicine, Niigata City, Japan.

Natural history of chronic hepatitis C
Canadian Association for the Study of the Liver

Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus
Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA, Tanabe KK Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston.USA Cancer Res 2000 Jun 1;60(11):2790-5

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Department of Gastroenterology, University of Tokyo, Japan. Ann Intern Med 1999 Aug 3;131(3):174-81

Effect of transcatheter arterial chemoembolization on kidney hemodynamics and function in patients with cirrhosis and hepatocellular carcinoma
Nakano R, Iwao T, Oho K, Ono N, Sakai T, Sato M, Yamawaki M, Miyamoto Y, Sakai K, Takeda T, Tsuruta O, Sata M, Toyonaga A. Second Department of Medicine, Kurume University School of Medicine, Japan. J Hepatol 1999 Aug;31(2):340-6

High alpha-fetoprotein level in HCV-related nodular liver cell dysplasia
Ng FH, Chow KC, Cheng CS, Kng C, Ng WF, Wong BC. Department of Medicine, Ruttonjee Hospital, Wan Chai, Hong Kong, China. Am J Gastroenterol 1999 Aug;94(8):2296-7

Increased Risk of Hepatocellular Carcinoma in Male Hepatitis B Surface Antigen Carriers With Chronic Hepatitis Who Have Detectable Urinary Aflatoxin Metabolite M1
Zongtang Sun 1, Peixin Lu 2, Mitchell H. Gail 3, David Pee 4, Qinan Zhang 2, Lihua Ming 1, Jinbing Wang 2, Yan Wu 2, Guoting Liu 1, Yuying Wu 1, and Yuanrong Zhu 2.
1 Cancer Institute, National Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences, Beijing, China; 2 Liver Cancer Institute, Jiangsu, China; 3 National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda MD; and 4 Information Management Services, Rockville, MD. Hepatology, August 1999, p. 379-383, Vol. 30, No. 2

Should hepatomas be treated with hepatic resection or transplantation? Yamamoto J, Iwatsuki S, Kosuge T, Dvorchik I, Shimada K, Marsh JW, Yamasaki S, Starzl TE Department of Surgery, National Cancer Center Hospital, Tokyo, Japan. Cancer 1999 Oct 1;86(7):1151-8

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection
Baffis V, Shrier I, Sherker AH, Szilagyi A. Sir Mortimer B. Davis-Jewish General Hospital and McGill University, Montreal, Quebec, Canada. Ann Intern Med 1999 Nov 2;131(9):696-701

Cancer risk in primary biliary cirrhosis: a study in northern England
Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF. Department of Epidemiology and Public Health, The Medical School, Newcastle-upon-Tyne, UK. Gut 1999 Nov;45(5):756-60

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation
Llovet JM, Fuster J, Bruix J. Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Catalonia, Spain. Hepatology 1999 Dec;30(6):1434-40



Chi siamo Faq Links Reviews News E-mail Casi clinici Immagini